PT-141
Neuropeptides
£32.00per vial
PT-141 (bremelanotide) is a cyclic heptapeptide derived from alpha-melanocyte-stimulating hormone, acting as an agonist at the melanocortin MC3 and MC4 receptors. It is studied in controlled laboratory settings for melanocortin receptor binding, cAMP signalling, and central neuroendocrine pathways in hypothalamic and limbic tissue models.
For laboratory research only. Not for human consumption. No medical claims. This product is not intended to diagnose, treat, cure, or prevent any disease.
This vial is sealed for the protection of health and hygiene. Under regulation 28(1)(e) of the Consumer Contracts (Information, Cancellation and Additional Charges) Regulations 2013, the 14-day right to cancel is lost for this item once that seal is broken. While the seal is intact the right applies in full.
PT-141 cannot be listed to research users in Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates, United States. Verify local eligibility before ordering.
Listed
- Molecular weight
- 1025.2 g/mol
- Sequence
- Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
- Presentation
- Pre-mixed liquid, 3ml vial
For laboratory research only. Not for human consumption. No medical claims.
- UK DISPATCH
- TRACKED SHIPPING
- COA PER BATCH
- SECURE PAYMENT
§01Compound Profile
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
HPLC
Purity by chromatography
ANALYSED
MASS SPECTROMETRY
Identity confirmation
ANALYSED
PUBLIC COA
Every batch number resolves to its Certificate of Analysis
DOCUMENTED
§02The Science
Published constants and presentation for PT-141, as catalogued.
Every figure in this list is a published constant or a presentation fact. None of it is an analytical result: the measured figures live on the Certificate of Analysis for the batch.
- Molecular weight
- 1025.2 g/mol
- Sequence
- Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-OH
- Presentation
- Pre-mixed liquid, 3ml vial
- Batch reference
- PT5611
Molecular weight source: PubChem CID 9941379 (bremelanotide).
§03Certificate of Analysis
Every batch is independently analysed by HPLC and mass spectrometry before it is listed, and the Certificate of Analysis for that batch is published in full, including the measured purity figure for that batch.
| PARAMETER | METHOD | RESULT |
|---|---|---|
| Purity | HPLC | 98.9% |
| Identity | Mass spectrometry | Confirmed |
PT5611 · 2026-07-07
§04Compound details
PT-141 (bremelanotide) is a cyclic seven-residue peptide derived from alpha-melanocyte-stimulating hormone. The cyclic backbone constrains the pharmacophore and is what shifts receptor selectivity away from MC1R, the pigmentation receptor, toward the central subtypes MC3R and MC4R. That selectivity profile is the reason it is used as a pharmacological tool to separate central melanocortin signalling from peripheral pigmentary effects.
MC3R and MC4R are class A G protein-coupled receptors coupled through Gs to adenylyl cyclase. Agonist binding raises intracellular cAMP and activates protein kinase A, with downstream CREB phosphorylation. MC4R in particular is densely expressed in the paraventricular nucleus of the hypothalamus and in limbic structures, and its signalling is antagonised endogenously by agouti-related peptide, which gives laboratory models a defined counterparty for competitive binding work.
Controlled research applications include receptor-binding and functional cAMP assays that profile MC3R and MC4R selectivity, studies of central neuroendocrine circuitry in the hypothalamus and limbic system, and comparative work against MC1R-selective analogues to isolate subtype contributions. It also appears as a reference agonist in melanocortin system studies where a non-pigmentary probe is required. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
PT-141 is listed as a pre-mixed liquid in a sealed 3ml vial, at 10mg and 20mg. It requires no reconstitution and no diluent.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry against the expected mass, which for a cyclic peptide also distinguishes the intended cyclised species from its linear precursor. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a lot number that resolves to the public Certificate of Analysis for its batch, published in full, including the raw chromatograms rather than a summary figure, together with the lot reference, the analysis date, and the laboratory that ran it.
Research Use Only
PT-141 is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about PT-141. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for PT-141 relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
PT-141 cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates, United States. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
Research Context
PT-141 (bremelanotide) is a cyclic seven-residue peptide derived from alpha-melanocyte-stimulating hormone. The cyclic backbone constrains the pharmacophore and is what shifts receptor selectivity away from MC1R, the pigmentation receptor, toward the central subtypes MC3R and MC4R. That selectivity profile is the reason it is used as a pharmacological tool to separate central melanocortin signalling from peripheral pigmentary effects.
MC3R and MC4R are class A G protein-coupled receptors coupled through Gs to adenylyl cyclase. Agonist binding raises intracellular cAMP and activates protein kinase A, with downstream CREB phosphorylation. MC4R in particular is densely expressed in the paraventricular nucleus of the hypothalamus and in limbic structures, and its signalling is antagonised endogenously by agouti-related peptide, which gives laboratory models a defined counterparty for competitive binding work.
Controlled research applications include receptor-binding and functional cAMP assays that profile MC3R and MC4R selectivity, studies of central neuroendocrine circuitry in the hypothalamus and limbic system, and comparative work against MC1R-selective analogues to isolate subtype contributions. It also appears as a reference agonist in melanocortin system studies where a non-pigmentary probe is required. No therapeutic, diagnostic, or clinical conclusion is drawn from any study referenced above, and none should be inferred.
Analysis and Documentation
PT-141 is listed as a pre-mixed liquid in a sealed 3ml vial, at 10mg and 20mg. It requires no reconstitution and no diluent.
Every batch is independently analysed before it is listed. Purity is measured by high-performance liquid chromatography. Identity is confirmed by mass spectrometry against the expected mass, which for a cyclic peptide also distinguishes the intended cyclised species from its linear precursor. Those are the two analytical methods used, and no other method is claimed.
Each vial carries a lot number that resolves to the public Certificate of Analysis for its batch, published in full, including the raw chromatograms rather than a summary figure, together with the lot reference, the analysis date, and the laboratory that ran it.
Compliance Notice
Research Use Only
PT-141 is catalogued strictly for in-vitro laboratory research. It is not for human consumption, veterinary use, or therapeutic, diagnostic or clinical application. It is not supplied as a medicinal product and it is not licensed by the MHRA.
Not a Medical Product
None of the compounds listed on this site are medicinal products, nor should they be marketed, described or used as such. No medical claims are made about PT-141. Nothing on this page is medical, veterinary or scientific advice, and no guidance on preparation, administration or quantity is provided or will be provided on request.
Compliance and Responsibility
The research user is responsible for ensuring compliance with all laws and regulations governing the receipt, handling, storage, use and disposal of research chemicals in their jurisdiction, and for applying appropriate control measures under the Control of Substances Hazardous to Health Regulations 2002 or the equivalent local regime.
Analytical Scope
Analytical results published for PT-141 relate solely to the batch identified on the Certificate of Analysis. Two methods are used: high-performance liquid chromatography and mass spectrometry. No other analysis is performed or implied. Results for one batch do not warrant any other batch.
Jurisdiction Notice
PT-141 cannot be listed to research users in the following jurisdictions: Australia, Canada, Japan, Mexico, New Zealand, Norway, Russian Federation, Saudi Arabia, Singapore, South Korea, Switzerland, United Arab Emirates, United States. It is the research user's responsibility to verify local eligibility before placing an order. Where an order is placed for a jurisdiction in which the compound cannot be listed, the order will be cancelled and refunded in full.
§05Related compounds
§06Questions
No. PT-141 is catalogued strictly for in-vitro laboratory research. It is not for human or veterinary consumption and no medical claims are made.
Melanocortin receptor binding and selectivity, cAMP signalling through Gs-coupled receptors, and central neuroendocrine pathways in hypothalamic and limbic tissue models.
MC3R and MC4R, with reduced activity at MC1R relative to linear alpha-MSH analogues. That subtype profile is why it is used as a non-pigmentary melanocortin probe.
Pre-mixed liquid in a sealed 3ml vial, at 10mg and 20mg. No reconstitution is required.
HPLC for purity and mass spectrometry for identity, on every batch, before it is listed. For a cyclic peptide, mass spectrometry also distinguishes the cyclised species from its linear precursor. No further assay is claimed.
Every batch has a document.
The Certificate of Analysis for a batch is published when that batch is released. Your batch number resolves to the report.
For laboratory research only. Not for human consumption. No medical claims.
